PSY180 - UK HEALTH TECHNOLOGY ASSESSMENT OF ORPHAN DRUGS FOR RARE ONCOLOGY VERSUS RARE DISEASE- DOES ORPHAN DESIGNATION MAKE ANY DIFFERENCE IN HTA PROCESS?
Abstract
Authors
S. Kelly
S. Kelly
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now